Industries > Pharma > Global Anti-Obesity Drugs Market Forecast 2018-2028

Back to Pharma Reports

Global Anti-Obesity Drugs Market Forecast 2018-2028

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

PUBLISHED: 20 November 2018

PAGES: 250

PRODUCT CODE: PHA0343

SUBMARKET: Therapeutic Drugs

SKU: PHA0343 Categories: Pharma, Therapeutic Drugs Tags: PHA0343, PHA0352, PHA0416, PHA0438

The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 119 tables and 139 figures– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Anti-obesity Drugs Market forecast from 2018-2028

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
• Incretion mimetics/GLP-1 agonists
• SNDRIs
• Lipase Inhibitors
• Serotonin receptor agonists
• Sympathomimetic-GABA receptor agonists
• Sympathomimetics

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy:
• Long-term Drugs
• Short-term Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs:
• Innovator
• Generic Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC:
• Prescription Drugs
• OTC

• This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs:
• Saxenda
• Contrave/Mysimba
• Belviq
• Qysmia
• Xenical
• Alli

• This report provides individual revenue forecasts from 2018-2028 for these regional and national markets:
• US
• Japan
• EU5: Germany, France, Spain, Italy, UK
• BRIC: Brazil, Russia, China, India
• RoW

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs

• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:
• Eisai/Arena
• GlaxoSmithKline (GSK)
• Novo Nordisk
• Orexigen/Takeda
• Roche
• Teva
• Vivus

• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.

• This report gives an overview of pricing and reimbursement in the US and EU.

• This report provides a SWOT Analysis of the global anti-obesity drugs market.

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

Buy our report today Anti-obesity Drugs Market Analysis : Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview

1.1 Why You Should Read This Report

1.2 How This Report Delivers

1.3 Key Questions Answered by This Analytical Report:

1.4 Who is This Report for?

1.5 Methodology

1.5.1 Primary Research

1.5.2 Secondary Research

1.5.3 Market Evaluation & Forecasting Methodology

1.6 Frequently Asked Questions

1.7 Associated Reports

1.8 About Visiongain

2. Introduction to Obesity

2.1 What is Obesity?

2.1.1 Types of obesity

2.1.1.1 Central Obesity / Android Type

2.1.1.2 Peripheral Obesity/ Gynoid Type

2.2 What are the causes and risk factors of obesity?

2.2.1 Energy Imbalance

2.2.2 Genetic Predisposition

2.2.3 Unhealthy Diet

2.2.4 Health Conditions and Medicines

2.2.5 Emotional Factors

2.2.6 Age

2.2.7 Pregnancy

2.2.8 Lack of Sleep

2.2.9 Smoking

2.3 Obesity Measurement

2.3.1 BMI

2.3.2 Waist circumference

2.3.3 Index of Central Obesity

2.3.4 Bioelectrical Impedance Analysis

2.3.5 New Approaches/Techniques

2.4 Epidemiology of Obesity

2.4.1 Epidemiology by Geography

2.4.2 Epidemiology by Country

2.4.3 Historical Prevalence in Major Markets

2.4.4 Forecast of Obesity Prevalence in Major Markets

2.5 Humanistic and Economic Burden

2.5.1 Mortality

2.5.2 Morbidity

2.5.2.1 Disability-adjusted life year (DALY)

2.5.2.2 Years Lost due to Disability (YLD)

2.5.2.3 Years of Life Lost (YLL)

2.5.3 Economic Impact

2.6 Obesity: Prevention and Treatment

2.6.1 Lifestyle changes

2.6.2 Pharmacotherapy

2.6.3 Other treatments

3. Introduction to the Global Anti-obesity Drugs Market

3.1 Market Structure

3.2 Market Definition and Scope

3.3 Classification by Mechanism of Action

3.3.1 Incretin Mimetics/GLP-1 Agonists

3.3.2 Lipase Inhibitors

3.3.3 Serotonin-norepinephrine-dopamine Reuptake (SNDRI) Inhibitors

3.3.4 Serotonin Receptor Agonists

3.3.5 Sympathomimetics

3.3.6 Sympathomimetic-GABA Receptor Agonists

3.3.7 Others

3.4 Classification by Innovator or Generics Drugs

3.4.1 Innovator Drugs

3.4.2 Generics Drugs

3.5 Classification by Prescription or OTC drugs

3.5.1 Prescription drugs

3.5.2 OTC drugs

3.6 Classification by Duration of Therapy

3.6.1 Short-term drugs

3.6.2 Long-term drugs

4. Global Anti-obesity Drugs Market 2018-2028

4.1 Global Anti-obesity Drugs Market 2017

4.2 Global Anti-obesity Drugs Market Forecast 2017-2028

4.3 Global Anti-obesity Drugs by Mechanism of Action

4.3.1 Global Anti-obesity Drugs by Mechanism of Action: Market Forecasts 2018-2028

4.3.1.1 Incretin mimetics/GLP-1 Agonists: Market Forecasts 2018-2028

4.3.1.2 Lipase Inhibitors: Market Forecasts 2018-2028

4.3.1.3 Serotonin-norepinephrine-dopamine Reuptake Inhibitors (SNDRI): Market Forecasts 2018-2028

4.3.2 Serotonin Receptor Agonists: Market Forecasts 2018-2028

4.3.2.1 Sympathomimetic-GABA Receptor Agonists: Market Forecasts 2018-2028

4.3.2.2 Sympathomimetics: Market Forecasts 2018-2028

4.3.2.3 Others: Market Forecasts 2018-2028

4.3.3 Global Anti-obesity Drugs Market Forecasts by Mechanism of Action: Market Share 2018-2028

4.4 Global Anti-obesity Drugs Market by Innovator and Generics Drugs

4.4.1 Global Anti-obesity Drugs by Innovator Drugs and Generics: Market Forecasts 2018-2028

4.4.1.1 Innovator Drugs: Market Forecasts 2018-2028

4.4.1.2 Generics: Market Forecasts 2018-2028

4.4.2 Global Anti-obesity Drugs Market Forecast by Innovator Drugs and Generics: Market Share 2018-2028

4.5 Global Anti-obesity Drugs Market by Prescription and OTC Drugs

4.5.1 Global Anti-obesity Drugs Market by Prescription and OTF Drugs: Market Forecast 2018-2028

4.5.1.1 Prescription Drugs: Market Forecasts 2018-2028

4.5.1.2 OTC Drugs: Market Forecasts 2018-2028

4.5.2 Global Anti-obesity Drugs Market Forecast by Prescription and OTC Drugs: Market Share 2018-2028

4.6 4.6 Global Anti-obesity Drugs Market by Duration of Therapy

4.6.1 Global Anti-obesity Drugs Market by Duration of Therapy: Market Forecast 2017-2028

4.6.1.1 Short-term Anti-obesity Drugs: Market Forecasts 2018-2028

4.6.1.2 Long-term Anti-obesity Drugs: Market Forecasts 2018-2028

4.6.2 Global Anti-obesity Drugs Market Forecast by Duration of Therapy: Market Share 2017-2028

4.7 Overall Global Anti-obesity Drugs Market Drivers, Restraints and Trends

5. Leading Anti-obesity Drugs

5.1 Snapshot of Anti-obesity Drugs

5.2 Innovator Drugs

5.2.1 Saxenda

5.2.1.1 Saxenda Drug Profile

5.2.1.2 Saxenda Historical Sales

5.2.1.3 Saxenda Forecast 2018-2028

5.2.1.4 Saxenda Sales by Geography, 2017

5.2.2 Contrave / Mysimba

5.2.2.1 Contrave Drug Profile

5.2.2.2 Contrave Historical Sales

5.2.2.3 Contrave Forecast 2018-2028

5.2.2.4 Contrave Sales by Geography, 2017

5.2.3 Belviq

5.2.3.1 Belviq Drug Profile

5.2.3.2 Belviq Historical Sales

5.2.3.3 Belviq Forecast 2018-2028

5.2.3.4 Belviq Sales by Geography, 2017

5.2.4 Qysmia

5.2.4.1 Qysmia Drug Profile

5.2.4.2 Qysmia Historical Sales

5.2.4.3 Qysmia Forecast 2018-2028

5.2.4.4 Qysmia Sales by Geography, 2017

5.2.5 Xenical and Alli

5.2.5.1 Xenical and Alli Historical Sales

5.2.5.2 Xenical and Alli Sales by Geography, 2017

5.2.5.3 Xenical and Alli Forecast 2018-2028

5.2.6 Cametor/Oblean

5.2.7 Lomaira

5.3 Generics

5.3.1 Orlistat

5.3.1.1 Orlistat Historical Sales

5.3.2 Sibutramine

5.3.2.1 Sibutramine Historical Sales

5.3.3 Adipex

5.3.3.1 Adipex Historical Sales

5.3.4 Phentermine

5.3.4.1 Phentermine Historical Sales

6. Leading National Markets Forecast 2018-2028

6.1 Geographical Breakdown of Global Anti-obesity Drugs Market, 2017

6.1.1 Regional Breakdown of Global Anti-obesity Drugs Market, 2017

6.1.2 Country Breakdown of Global Anti-obesity Drugs Market, 2017

6.2 Regional Forecast of Global Anti-obesity Drugs Market, 2018-2028

6.3 US Anti-obesity Drugs Market

6.3.1 US Anti-obesity Drugs: Market Forecasts 2018-2028

6.4 Japan Anti-obesity Drugs Market

6.4.1 Japan Anti-obesity Drugs: Market Forecasts 2018-2028

6.5 EU5 Anti-obesity Drugs Market, 2017

6.5.1 EU5 Anti-obesity Drugs: Market Forecast 2018-2028

6.5.1.1 The UK Anti-obesity Drugs: Market Forecasts 2018-2028

6.5.1.2 Germany Anti-obesity Drugs: Market Forecasts 2018-2028

6.5.1.3 France Anti-obesity Drugs: Market Forecasts 2018-2028

6.5.1.4 Italy Anti-obesity Drugs: Market Forecasts 2018-2028

6.5.1.5 Spain Anti-obesity Drugs: Market Forecasts 2018-2028

6.6 BRIC Anti-obesity Drugs Market, 2017

6.6.1 BRIC Anti-obesity Drugs: Market Forecasts 2018-2028

6.6.1.1 China Anti-obesity Drugs: Market Forecasts 2018-2028

6.6.1.2 India Anti-obesity Drugs: Market Forecasts 2018-2028

6.6.1.3 Brazil Anti-obesity Drugs: Market Forecasts 2018-2028

6.6.1.4 Russia Anti-obesity Drugs: Market Forecasts 2018-2028

7. Research and Development for Treating Obesity

7.1 Novel Mechanism of Action of Pipeline Drugs

7.2 Active Pipeline Molecules

7.3 Promising Potential Pipeline Molecules

7.3.1 Phase III Molecules

7.3.1.1 BTI-320

7.3.2 Phase II Molecules

7.3.2.1 Oxyntolong

7.3.2.2 Antisense FGFR4 oligo, Verva

7.3.2.3 S-237648

7.3.2.4 Setmelanotide

7.3.2.5 Bupropion + zonisamide SR

7.3.2.6 Semaglutide

7.3.2.7 LIK066

7.3.2.8 Tesofensine

7.3.2.9 LIPO-202

7.3.2.10 Canagliflozin and Phentermine

7.3.2.11 OBEP-100

7.3.2.12 Efpeglenatide

7.3.2.13 EMP16

7.3.2.14 MEDI-0382

8. Pricing and Reimbursement Overview

8.1 US

8.2 EU

8.3 Payers Perspective

9. Qualitative Analysis of the Global Anti-obesity Drugs Market

9.1 SWOT Analysis, 2017

10. Leading Companies in Global Anti-obesity Drugs Market, 2017

10.1 Novo Nordisk

10.1.1 Obesity Care – To Establish its presence

10.2 Orexigen/Takeda

10.2.1 Collaboration Agreement with Takeda Pharmaceutical Company Limited

10.2.2 Collaboration Agreement with Valeant

10.3 Arena/Eisai

10.3.1 Collaboration Agreement with Eisai Co., Ltd.

10.3.2 Collaboration Agreement with Other Companies

10.4 F. Hoffmann-La Roche Ltd.

10.5 Vivus

10.6 Teva

10.7 GlaxoSmithKline (GSK)

11. Conclusions

Associated visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Tables

Table 2.1: WHO BMI Cut Off Points

Table 2.2 Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risk

Table 3.1 Mechanism of Action of Innovator Drugs for the treatment of Obesity

Table 3.2 List of Innovator Drugs for the treatment of Obesity

Table 3.3 List of Prescription Drugs for the treatment of Obesity

Table 3.4 Long-term Prescription Drugs for the treatment of Obesity

Table 4.1 Global Anti-obesity Drugs Market by Markets: Revenue ($m), and Market Share (%), 2017

Table 4.2 Global Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.3 Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.4 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%)

Table 4.5 Global Anti-obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.6 List of Active GLP-1 agonists in Clinical Pipeline

Table 4.7 Global Anti-obesity Lipase Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.8 List of Active SNDRI agonists in Clinical Pipeline

Table 4.9 Global Anti-obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.10 Global Anti-obesity Serotonin Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.11 Global Anti-obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.12 Global Anti-obesity Sympathomimetic Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.13 Global Anti-obesity Other Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.14 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Market Share (%)

Table 4.15 Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.16 Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics 2017-2028: AGR (%)

Table 4.17 Global Anti-obesity Innovator Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.18 Global Anti-obesity Generic Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.19 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Market Share (%)

Table 4.20 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.21 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: AGR (%)

Table 4.22 Global Anti-obesity Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.23 Global Anti-obesity OTC Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.24 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Market Share (%)

Table 4.25 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.26 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: AGR (%)

Table 4.27 Global Anti-obesity Short-term Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 4.28 Global Anti-obesity Long-term Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 5.1 Saxenda Drug Profile

Table 5.2 Saxenda Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 5.3 Contrave Drug Profile

Table 5.4 Contrave Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 5.5 Belviq Drug Profile

Table 5.6 Belviq Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 5.7 Qysmia Drug Profile

Table 5.8 Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 5.9 Alli Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.1 Global Anti-obesity Drugs Market by Region: Revenue ($m), and Market Share (%), 2017

Table 6.2 Global Anti-obesity Drugs Market by Country: Revenue ($m), and Market Share (%), 2017

Table 6.3 Global Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.4 Global Anti-obesity Drugs Market by Region: AGR 2017-2028 (%)

Table 6.5 Global Anti-obesity Drugs Market by Region: Market Share (%), 2017-2028

Table 6.6 US Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.7 U.S. Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.8 U.S. Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.9 US Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.10 US Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.11 Japan Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.12 Japan Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.13 Japan Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.14 Japan Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.15 Japan Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.16 EU5 Anti-obesity Drugs Market by Region: Market Size ($m) and Share (%), 2017

Table 6.17 EU5 Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.18 EU5 Anti-obesity Drugs Market by Region: Market Share Forecast 2017-2028 (%)

Table 6.19 EU5 Anti-obesity Drugs Market Forecast by Region: AGR (%) 2017-2028

Table 6.20 UK Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.21 UK Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.22 UK Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.23 UK Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.24 UK Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.25 Germany Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.26 Germany Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.27 Germany Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.28 Germany Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.29 Germany Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.30 France Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.31 France Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.32 France Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.33 France Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.34 France Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.35 Italy Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.36 Italy Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.37 Italy Anti-obesity Drugs Market Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.38 Italy Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.39 Italy Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.40 Spain Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.41 Spain Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.42 Spain Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.43 Spain Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.44 Spain Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.45 Anti-obesity Drugs Market in the BRIC Region: Market Size ($m) & Share 2017 (%)

Table 6.46 BRIC Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.47 China Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.48 China Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.49 China Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.50 China Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.51 China Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.52 India Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.53 India Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.54 India Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.55 India Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.56 India Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.57 Brazil Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.58 Brazil Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.59 Brazil Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.60 Brazil Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.61 Brazil Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.62 Russia Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.63 Russia Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.64 Russia Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.65 Russia Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 6.66 Russia Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)

Table 7.1 Active Pipeline Molecules under Development for Treating Obesity

Table 10.1: Innovator Drugs’ Originator-Licensee Information

Table 10.2 Novo Nordisk A/S: Overview

Table 10.3 Novo Nordisk: List of Active Clinical Pipeline Molecules

Table 10.4 Orexigen: Overview

Table 10.5 Arena: Overview

Table 10.6 Roche: Overview

Table 10.7 Vivus: Overview

Table 10.8 Teva: Overview

Table 10.9 Vivus: Overview

List of Figures

Figure 2.1 Prevalence of Obesity by WHO region, ages 18+, Both sexes, 2014

Figure 2.2 Prevalence of Overweight, ages 18+, 2010-2014, age standardized estimate: Both sexes 2014

Figure 2.3 Prevalence of Obesity, ages 18+, 2010-2014, age standardized estimate: Both sexes 2014

Figure 2.4 Prevalence of Obesity in OECD 32 Countries – population aged 15 years and over, 2013 or nearest year

Figure 2.5 Prevalence of Obesity in G7 and BRIC Countries – population aged 15 years and over, 2012 or nearest year, men, women, both sexes

Figure 2.6 Age-Standardized Obesity Prevalence Rate in Major Markets – Population aged 15 years and over, 1973-2012

Table 2.7 Forecast of Obesity Prevalence in Major Markets (US, EU5, BRIC, and Japan), Both Sexes, aged >18 years, 2017-2028, million, CAGR% (2017-2028)

Figure 2.8 Deaths due to Obesity in G7 and BRIC Nation: Absolute Number (000’s), 2015

Figure 2.9 DALY’s due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015

Figure 2.10 YLD’s due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015

Figure 2.11 YLL’s due to Obesity in G7 and BRIC Nation: Absolute Number (000’s), 2015

Figure 3.1 Global Anti-obesity Drugs Market Segmentation Overview

Figure 3.2 Anti-Obesity Drugs Classification by Mechanism of Action, 2017

Figure 4.1 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2017

Figure 4.2 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2017

Figure 4.3 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017

Figure 4.4 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017

Figure 4.5 Global Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)

Figure 4.6 Global Anti-obesity Drugs Market by Mechanism of Action 2017, Revenue ($m)

Figure 4.7 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2017

Figure 4.8 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), Global AGR (%)

Figure 4.9 Global Anti-obesity Drugs Market by Mechanism of Action 2017 and 2028: Revenue ($m), CAGR (%) 2017-2028

Figure 4.10 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%)

Figure 4.11 Global Anti-obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.12 Global Anti-obesity Lipase Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.13 Global Anti-obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.14 Global Anti-obesity Serotonin Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.15 Global Anti-obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.16 Global Anti-obesity Sympathomimetic Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.17 Global Anti-obesity Other Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.18 Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2017-2028: Market Share (%)

Figure 4.19 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2022

Figure 4.20 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2028

Figure 4.21 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Revenue ($m), 2017

Figure 4.22 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2017

Figure 4.23 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), Global AGR (%)

Figure 4.24 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%)

Figure 4.25 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%)

Figure 4.26 Global Anti-obesity Innovator Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.27 Global Anti-obesity Generic Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.28 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Market Share (%)

Figure 4.29 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2022

Figure 4.30 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2028

Figure 4.31 Global Anti-obesity Drugs Market by Prescription and OTC Drugs, Revenue 2017 ($m)

Figure 4.32 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017

Figure 4.33 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), Global AGR (%)

Figure 4.34 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%)

Figure 4.35 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: AGR (%)

Figure 4.36 Global Anti-obesity Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.37 Global Anti-obesity OTC Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.38 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Market Share (%)

Figure 4.39 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017

Figure 4.40 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2028

Figure 4.41 Global Anti-obesity Drugs Market by Duration of Therapy: Revenue ($m), 2017

Figure 4.42 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017

Figure 4.43 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%)

Figure 4.44 Global Anti-obesity Drugs Market by Duration of Therapy: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%)

Figure 4.45 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: AGR (%)

Figure 4.46 Global Anti-obesity Short-term Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.47 Global Anti-obesity Long-term Drugs Market 2017-2028: Revenue ($m), AGR (%)

Figure 4.48 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Market Share (%)

Figure 4.49 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017

Figure 4.50 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2028

Figure 4.51 Global Anti-obesity Drugs Market: Drivers and Restraints

Figure 4.52 Trends in Global Anti-obesity Drugs Market

Figure 5.1 Leading Anti-obesity Drug Sales, Revenue ($m), 2017

Figure 5.2 Leading Anti-obesity Drug Sales, Market Share (%), 2017

Figure 5.3 Anti-obesity Drugs Sales Forecast, Market Share (%), 2028

Figure 5.4 Leading Anti-obesity Drugs: Historical Revenue ($m), 2012-2017

Figure 5.5 Global Anti-obesity Innovator Drugs by Individual Drug: Market Share (%), 2017

Figure 5.6 Global Anti-obesity Innovator Drugs by Individual Drug: Market Share (%), 2028

Figure 5.7 Saxenda Global Sales: Revenue ($million), 2015-2016

Figure 5.8 Saxenda Sales Forecast 2017-2028: Revenue ($m), AGR (%)

Figure 5.9 Saxenda Sales by Geography: Market Share (%), 2017

Figure 5.10 Contrave Global Sales: Revenue ($million), 2014-2016

Figure 5.11 Contrave Sales Forecast 2017-2028: Revenue ($m), AGR (%)

Figure 5.12 Contrave Sales by Geography: Market Share (%), 2017

Figure 5.13 Belviq Global Sales: Revenue ($million), 2013-2016

Figure 5.14 Belviq Sales Forecast 2017-2028: Revenue ($million), AGR (%)

Figure 5.15 Belviq Sales by Geography: Market Share (%), 2017

Figure 5.16 Qysmia Global Sales: Revenue ($m), 2013-2016

Figure 5.17 Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%)

Figure 5.18 Qysmia Sales by Geography: Market Share (%), 2017

Figure 5.19 Xenical Global Sales: Revenue ($million), 2011-2016

Figure 5.20 Alli Global Sales: Revenue ($million), 2011-2016

Figure 5.21 Xenical Sales by Geography: Market Share (%), 2017

Figure 5.22 Alli Sales by Geography: Market Share (%), 2017

Figure 5.23 Alli Sales Forecast 2017-2028: Revenue ($m), AGR (%)

Figure 5.24 Global Anti-obesity Generics Market by Individual Compound: Market Share (%), 2017

Figure 5.25 Orlistat Global Sales: Revenue ($m), 2011-2016

Figure 5.26 Sibutramine Global Sales: Revenue ($m), 2012-2017

Figure 5.27 Adipex Global Sales: Revenue ($m), 2012-2017

Figure 5.28 Phentermine Global Sales: Revenue ($m), 2012-2017

Figure 6.1 Global Anti-obesity Drugs Market Segmentation by Region/Country

Figure 6.2 Global Anti-obesity Drugs Market by Region: Revenue ($m), 2017

Figure 6.3 Global Anti-obesity Drugs Market by Region: Market Share (%), 2017

Figure 6.4 Global Anti-obesity Drugs Market by Country: Revenue ($m), 2017

Figure 6.5 Global Anti-obesity Drugs Market by Country: Market Share (%), 2028

Figure 6.6 Global Anti-obesity Drugs Market Forecast by Region: Revenue ($m), Global AGR (%), 2017-2028

Figure 6.7 Global Anti-obesity Drugs Market Forecast by Region 2017, 2022, 2028: Revenue ($m), CAGR 2017-2028 (%)

Figure 6.8 Global Anti-obesity Drugs Market by Region: AGR 2017-2028 (%)

Figure 6.9 Global Anti-obesity Drugs Market by Region: Market Share (%), 2017-2028

Figure 6.10 Global Anti-obesity Drugs Market by Region: Market Share (%), 2017

Figure 6.11 Global Anti-obesity Drugs Market by Region: Market Share (%), 2022

Figure 6.12 Global Anti-obesity Drugs Market by Region: Market Share (%), 2028

Figure 6.13 US Anti-obesity Drugs Market by Mechanism of Action: Market Share %, 2017

Figure 6.14 US Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)

Figure 6.15 Japan Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)

Figure 6.16 EU5 Anti-obesity Drugs Market by Region: Global Market Share (%), 2017

Figure 6.17 EU5 Anti-obesity Drugs Market by Region: Market Share (%), 2017

Figure 6.18 EU5 Anti-obesity Drugs Market Forecast by Region 2017-2028: Revenue ($m), AGR (%)

Figure 6.19 EU5 Anti-obesity Drugs Market by Region 2017 and 2028: Revenue ($m), CAGR 2017-2028 (%)

Figure 6.20 EU5 Anti-obesity Drugs Market by Region: Market Share Forecast 2017-2028 (%)

Figure 6.21 EU5 Anti-obesity Drugs Market Forecast by Region: Global Market Share (%), 2028

Figure 6.22 EU5 Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2023

Figure 6.23 EU5 Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2028

Figure 6.24 EU5 Global Anti-obesity Drugs Market Forecast by Region: AGR (%), 2017-2028

Figure 6.25 UK Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028

Figure 6.26 Germany Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028

Figure 6.27 France Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028

Figure 6.28 Italy Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028

Figure 6.29 Spain Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028

Figure 6.30 BRIC Anti-obesity Drugs Market by Region: Global Market Share 2017 (%)

Figure 6.31 BRIC Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)

Figure 6.32 BRIC Anti-obesity Drugs Market Forecast 2017 and 2028: Revenue ($m), CAGR 2017-2028 (%)

Figure 6.33 BRIC Anti-obesity Drugs Market Forecast by Region: Global Market Share (%), 2028

Figure 6.34 BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2017

Figure 6.35 BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2028

Figure 6.36 China Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028

Figure 6.37 India Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028

Figure 6.38 Brazil Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028

Figure 6.39 Russia Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028

Figure 7.1 Anti-obesity Clinical Pipeline Segmentation by Phase, 2017

Figure 7.2 Anti-obesity Pipeline Segmentation by Mechanism of Action, 2017

Figure 9.1 SWOT Analysis of the Global Anti-obesity Drugs Market

Figure 10.1 Global Anti-obesity Drugs Market by Company: Revenue ($m)

Figure 10.2 Global Anti-obesity Drugs Market by Company 2017: Market Share (%)

Figure 10.3 Novo Nordisk’s 20-year R&D journey in Obesity - Milestones of Saxenda

Figure 11.1 Global Anti-obesity Drugs Market by Region: Share (%), 2017 and 2028

ADial Pharmaceuticals

AEMPS

AIFA

HAS

Akrimax Pharmaceuticals

American Medical Association

Arena Pharmaceuticals

AstraZeneca

Biophytis

Boehringer Ingelheim

Boston Therapeutics

Diasome

Eisai

EMEA

Empros Pharma

FDA

G-BA

GenePreDiT

GlaxoSmithKline (GSK)

Hanmi

Ildong Pharmaceuticals

Intarcia Therapeutics

Ionis Pharmaceuticals

Janssen Pharmaceuticals

KT&G Life Sciences

KVK Tech

Kwang Dong

Medivation

Medlab Clinical

Neothetics

NGM Biopharmaceuticals

NICE

SMC

Novartis

Novo Nordisk

OPKO Health

Orexigen

Rhythm Pharmaceuticals

Roche

Saniona

Shionogi & Co., Ltd

Takeda

Teva

Valeant Pharmaceuticals

Virtici

Vivus

World Health Organization (WHO)

Xenetic Biosciences

Zafgen

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2018-2028

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2018-2028

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Antibiotics Market Report 2023-2033

The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

31 January 2023

READ

Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

31 January 2023

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

31 January 2023

READ

Visiongain Publishes Human Microbiome Market Report 2023-2033

The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

30 January 2023

READ

Industries > Pharma > Global Anti-Obesity Drugs Market Forecast 2018-2028

Back to Pharma Reports

Global Anti-Obesity Drugs Market Forecast 2018-2028

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

Download sample pages

Related reports

Global Diabetes Drugs Market 2017-2027

Global Infectious Disease Diagnostics Market Forecast 2017-2027

Biologics Market Trends and Forecasts 2018-2028

Generic Drugs Market Forecast 2019-2029

Generic Drugs Market Forecast 2018-2028

Indian Pharmaceutical Market Forecast 2019-2029

Top 25 Dermatological Drugs Manufacturers 2019

Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029

Global OTC Pharmaceutical Market Forecast 2018-2028

Dermatological Drugs Market Forecast 2018-2028

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Antibiotics Market Report 2023-2033

Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

Visiongain Publishes Human Microbiome Market Report 2023-2033

Our Clients